triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer#873409ClinicalTrials.gov
• BRCA and NACT in TNBC Patients#981817ClinicalTrials.gov
• Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer#435735ClinicalTrials.gov
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer#860236ClinicalTrials.gov
• Microbiome Immunotherapy Neoadjuvant Assessment#898240ClinicalTrials.gov
• Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)#143571ClinicalTrials.gov
• A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer#424182ClinicalTrials.gov
• A Study Of PF-06647263 In Patients With Advanced Solid Tumors#844872ClinicalTrials.gov
• Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial#872241ClinicalTrials.gov
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer#894271ClinicalTrials.gov
• MUC1 Vaccine for Triple-negative Breast Cancer#172406ClinicalTrials.gov
• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer#474751ClinicalTrials.gov
• A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden#840981ClinicalTrials.gov
• Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial#253006ClinicalTrials.gov
• A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer#195533ClinicalTrials.gov
• Evaluation of triple negative breast cancer with heterogeneous immune infiltration#268885IRIS
• NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup#485787Harvard DASH
• A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)#914028ClinicalTrials.gov
• Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer#383561ClinicalTrials.gov
• Study of Tremelimumab in Patients With Advanced Solid Tumors#889561ClinicalTrials.gov
• Synergistic Anticancer Activity of Annona muricata Leaf Extract and Cisplatin in 4T1 Triple-Negative Breast Cancer Cells#288169HAL (France)
• NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial#180386ClinicalTrials.gov
• Social disparities in the frequency and severity of triple-negative breast cancer at diagnosis in a university hospital in Paris, France: confronting race and ethnic blindness#229837HAL (France)
• Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients#1009460ClinicalTrials.gov
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer#915720ClinicalTrials.gov
• Study of Tumor and Blood Samples From Women With Breast Cancer#907644ClinicalTrials.gov
• BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making#337742IRIS
• A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer#366654ClinicalTrials.gov
• Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer#806129ClinicalTrials.gov
• Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy#860989ClinicalTrials.gov
• Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes#827694ClinicalTrials.gov
• The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy#303723ClinicalTrials.gov
• Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer#174934ClinicalTrials.gov
• Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation#454020ClinicalTrials.gov
• All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial#869038ClinicalTrials.gov
• A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha#829321ClinicalTrials.gov
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer#969666ClinicalTrials.gov
• Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer#875137ClinicalTrials.gov
• Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution#898848ClinicalTrials.gov
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer#245486ClinicalTrials.gov
• ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer#463711ClinicalTrials.gov
• TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer#801712ClinicalTrials.gov
• A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer#1010265ClinicalTrials.gov
• Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil#802060ClinicalTrials.gov
• 99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer#869894ClinicalTrials.gov
• A Window-of-opportunity Study of Pelareorep in Early Breast Cancer#968153ClinicalTrials.gov
• Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer#899753ClinicalTrials.gov
• Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients#903392ClinicalTrials.gov
• Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients#912500ClinicalTrials.gov
• Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.#329526ClinicalTrials.gov